When the Immune System Targets Platelets
Platelets may be tiny, but they play an essential role in helping the blood clot and preventing excessive bleeding. In people with immune thrombocytopenia, or ITP, the immune system mistakenly attacks and destroys platelets faster than the body can replace them. When platelet levels become very low, patients may experience easy bruising, bleeding, or other complications.
For some people, standard treatments can help bring platelet levels under control. Others, however, continue to struggle even after trying several different therapies.
A 2024 Phase I clinical trial explored whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) could offer another approach for patients with particularly difficult-to-treat ITP.
Testing UC-MSCs in Patients With Long-Term ITP
The study included 18 adults with chronic refractory ITP. These were not newly diagnosed patients, the median duration of the condition was more than six years, and most participants had already tried several treatments. In fact, 15 of the 18 patients had previously received five or more different therapies.
Researchers gave each participant UC-MSC infusions once a week for four weeks. Different doses were tested during the first part of the study before researchers moved forward with the higher dose for the expansion phase.
The goal was to learn two things: whether the treatment could be given safely and whether patients showed meaningful improvement in their platelet levels.
Encouraging Platelet Responses
After treatment, 8 of the 18 patients, or 44.4%, achieved the study’s definition of a platelet response. For these patients, platelet counts increased enough to meet the study criteria while bleeding was absent. Four participants reached a complete response during the study.
Researchers also found that the median time for responding patients to first reach a platelet count of at least 50 billion platelets per liter was 21 days. Considering how heavily treated this group had already been, those results gave researchers a reason to continue investigating the therapy.
The responses were not universal, and some lasted longer than others. Still, seeing platelet improvement in nearly half of a small group of patients with difficult-to-treat chronic ITP was an encouraging early finding.
Why UC-MSCs May Be Helpful
UC-MSCs are especially interesting in autoimmune research because their potential benefits may go beyond simply replacing damaged cells. Instead, these cells can interact with the immune system and release biological signals that may help influence an overly active immune response.
In ITP, that matters because the problem begins with the immune system mistakenly targeting the body’s own platelets. The researchers observed changes in immune-cell activity after treatment that suggested UC-MSCs may help reduce certain T-cell responses and encourage a more regulated immune environment.
That means the goal of the therapy is not simply to raise platelet numbers directly, but potentially to address some of the immune imbalance behind the condition.
What Did the Safety Results Show?
All 18 participants completed the full four-infusion treatment schedule. Thirteen patients experienced at least one treatment-emergent side effect, but most were mild or moderate and resolved either on their own or with short-term treatment. Common issues included fatigue and temporary changes in certain blood tests.
This finding is important and highlights why larger clinical trials and continued safety monitoring are necessary.
An Early Step Toward New Options for ITP
This was a small Phase I study without a placebo or comparison group, so it cannot yet show how UC-MSC therapy compares with established treatments. Still, the early results are interesting.
Nearly half of the participants achieved a platelet response, despite having long-standing ITP that had already proven difficult to treat. Just as importantly, the study adds to growing research exploring how umbilical cord-derived MSCs may help influence the immune system rather than simply replace damaged tissue.
Larger randomized studies with longer follow-up will be needed to better understand both effectiveness and safety. For now, this trial offers another example of how regenerative medicine is expanding into new areas, using the biological properties of UC-MSCs to explore ways of helping the immune system regain a healthier balance.
Source
Chen Y, Xu Y, Chi Y, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduction and Targeted Therapy. 2024;9:102. doi: 10.1038/s41392-024-01793-5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11039759/
Related Treatment Pages